Eren Taydas, MD
Gastroenterology · Exton, PANPI 1902164742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,697 and has fallen 54.6% since, to $1,224 in 2025.
Across 496 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Bristol Myers Squibb$1K
- Johnson & Johnson$891
- Takeda Pharmaceuticals U.S.A., Inc.$888
- Pfizer$406
- plus $3K from 24 others
What the payments were for
- Consulting fees$170%
- Food & beverage$8,85699%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,724 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 65 | $1,073 |
| Bristol Myers Squibb | 59 | $1,022 |
| Johnson & Johnson | 41 | $891 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $888 |
| Pfizer | 28 | $406 |
| Gilead | 31 | $404 |
| Ardelyx, Inc. | 13 | $329 |
| Madrigal Pharmaceuticals | 11 | $253 |
| Redhill Biopharma Inc. | 16 | $238 |
| Intercept Pharmaceuticals, Inc. | 11 | $206 |
| Merck | 13 | $201 |
| Phathom Pharmaceuticals, Inc. | 11 | $201 |
| Sanofi | 7 | $167 |
| Lilly USA, LLC | 8 | $160 |
| Ipsen Biopharmaceuticals, Inc | 6 | $150 |
| Regeneron Healthcare Solutions, Inc. | 6 | $125 |
| QOL Medical, LLC | 4 | $99 |
| Nestle Healthcare Nutrition Inc. | 4 | $86 |
| Braintree Laboratories, Inc. | 4 | $63 |
| Celltrion USA Inc. | 2 | $57 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Palette Life Sciences, Inc. | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Concordia Pharmaceuticals Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $16 |
| Boston Scientific | 1 | $11 |
How this compares
$8,942 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 142 | $1,024 |
| Omeprazole | 25 | $123 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Exton
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Kofi ClarkeHershey$426K
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Elie AounPittsburgh$323K
- Andrew TinsleyHershey$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.